文献速递糖尿病

前蛋白转化酶枯草溶菌素/kexin 9型(PCSK9)抑制剂与新发2型糖尿病:一项纳入超过96,000患者年的系统评价与Meta分析

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.
PubMed 文献 · Diabetes Care · 2017-11-27

该Meta分析纳入20项随机临床试验共68,123例原发性高胆固醇血症患者,评估PCSK9抑制剂对比安慰剂对新发糖尿病的影响。PCSK9抑制剂使空腹血糖和HbA1c轻度升高,但未显著增加糖尿病发病率(RR 1.04)。探索性分析提示糖尿病风险增加与治疗强度及持续时间相关。

要点

  • PCSK9抑制剂对比安慰剂使空腹血糖升高1.88 mg/dL,HbA1c升高0.032%。
  • 糖尿病发病率无显著增加(RR 1.04,95%CI 0.96-1.13,P=0.427)。
  • 探索性分析提示糖尿病风险与PCSK9抑制剂治疗强度(P=0.029)和持续时间(P=0.026)相关。

核心结论

  • 短期PCSK9抑制剂治疗使血浆血糖和HbA1c出现小幅但显著的升高。

研究设计与样本

  • 系统评价与Meta分析,纳入20项2/3期随机临床试验(RCT),评估PCSK9抑制剂对比安慰剂在原发性高胆固醇血症中的效果。
  • 共纳入68,123例参与者,中位随访78周;98.4%的研究中他汀和依折麦布的使用在PCSK9抑制剂组与安慰剂组间平衡。

主要发现

  • PCSK9抑制剂对比安慰剂使空腹血糖升高(加权均数差1.88 mg/dL,95%CI 0.91-2.68,I²=0%,P<0.001)。
  • PCSK9抑制剂对比安慰剂使HbA1c升高(0.032%,95%CI 0.011-0.050,I²=15.5%,P<0.001)。
  • 糖尿病发病率无显著增加(RR 1.04,95%CI 0.96-1.13,I²=0%,P=0.427)。
  • 探索性Meta回归分析提示糖尿病风险增加与PCSK9抑制剂治疗强度(P=0.029)和持续时间(P=0.026)相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Like mutations with loss of function in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, inhibitors of PCSK9 (PCSK9i) may potentially favor the manifestation of diabetes. RESEARCH DESIGN AND METHODS: A meta-analysis of phase 2/3 randomized clinical trials (RCTs) assessed PCSK9i versus placebo in the primary hypercholesterolemia setting. Statins and ezetimibe were used in 98.4% of these studies and balanced between PCSK9i and placebo. We calculated relative risks (RRs) and 95% CIs using random- and fixed-effect models. RESULTS: We included 68,123 participants (20 RCTs) with median follow-up of 78 weeks. PCSK9i increased fasting blood glucose (weighted mean difference 1.88 mg/dL [95% CI 0.91-2.68]; I2 = 0%; P < 0.001) and HbA1c (0.032% [0.011-0.050]; I2 = 15.5%; P < 0.001) when compared with placebo. This effect was not sufficient to increase incidence of diabetes (RR 1.04 [0.96-1.13]; I2 = 0%; P = 0.427). Exploratory meta-regression analyses indicated an association between the increased risk of diabetes and the potency (P = 0.029) and duration (P = 0.026) of PCSK9i treatment. CONCLUSIONS: In the short term, PCSK9i therapy favors a small but significant increase in plasma glycemia and HbA1c.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. de Carvalho LSF, Campos AM, Sposito AC, et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care. 2017. PMID: 29180351. doi:10.2337/dc17-1464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。